心血管风险评估工具对代谢功能障碍相关脂肪性肝病患者不足
研究纳入TARGET-NASH研究中1090例30岁及以上美国成人代谢功能障碍相关脂肪性肝病(MASLD)患者,评估FRS、PCE和PREVENT方程对5至10年心血管事件的预测准确性。结果显示FRS和PREVENT模型的区分能力较弱(C统计量分别为0.58和0.60),FRS和PCE校准显著不佳(P<0.01),提示常用工具在MASLD人群中表现不佳。
要点
- FRS识别心血管事件的C统计量为0.58(95%CI 0.52-0.63),PREVENT模型为0.60(95%CI 0.54-0.65),区分能力均较弱。
- FRS和PCE均显示显著校准不良(P<0.01),在高十分位组高估风险、低十分位组低估风险。
- 观察到的CV事件从代谢功能障碍相关脂肪性肝到肝硬化呈增加趋势。
核心结论
- 常用心血管风险评估工具在MASLD患者队列中表现不佳,需要更好的风险评估工具。
研究设计与样本
- 分析纳入TARGET-NASH研究中1090例30岁及以上美国成人MASLD患者。
- 使用原始和重新校准的FRS与PCE以及原始PREVENT方程估计5至10年心血管风险。
- 采用Harrell一致性统计量评估区分度,采用改良Hosmer-Lemeshow检验比较观察与预测的心血管事件评估校准度,并采用逻辑回归评估肝病对观察心血管事件的贡献。
主要发现
- 共纳入1090例患者,观察到的CV事件从代谢功能障碍相关脂肪性肝到肝硬化增加。
- FRS识别后续发生CV事件患者的C统计量为0.58(95%CI 0.52-0.63),PREVENT模型为0.60(95%CI 0.54-0.65)。
- FRS和PCE均显示显著校准不良(P<0.01),在预测风险最高十分位组高估、最低十分位组低估。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Risk of cardiovascular (CV) events is estimated by the Framingham Risk Score (FRS), Pooled Cohort Equation (PCE), and the American Heart Association Predicting Risk of cardiovascular disease (CVD) EVENTs (PREVENT) equation. The applicability of these risk tools in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) is uncertain. This study sought to determine the accuracy of the FRS, PCE, and PREVENT in a real-world cohort of patients with MASLD. METHODS: This analysis included US adults 30 years and older with MASLD in the TARGET-NASH study. Five to ten-year CV risk was estimated using original and recalibrated versions of the FRS and PCE, and original PREVENT equation. Discrimination among prediction models was assessed using the Harrell concordance statistic, and calibration was evaluated using a modified Hosmer Lemeshow test comparing observed and predicted CV events. Logistic regression was used to assess the contribution of liver disease to observed CV events. RESULTS: Overall, 1,090 patients were included. There was an increase in observed CV events from metabolic dysfunction-associated steatotic livers to cirrhosis. FRS demonstrated a weak ability to identify patients who went on to experience a CV event (C-statistic 0.58, 95% confidence interval 0.52-0.63) as did the American Heart Association PREVENT model (C-statistic 0.60, 95% confidence interval 0.54-0.65). Both the FRS and PCE demonstrated a significant lack of calibration ( P < 0.01), with overestimation in the highest deciles and underestimation in the lowest deciles of predicted risk. DISCUSSION: Commonly used tools to identify CV risk performed poorly in a cohort of patients with MASLD. Because CV related death is the greatest source of mortality among patients with MASLD, better risk assessment tools are required.
引用
- Barritt AS, Tapper EB, Newsome PN, et al. Cardiovascular Risk Assessment Tools are Insufficient for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease. Am J Gastroenterol. 2025. PMID: 40498104. doi:10.14309/ajg.0000000000003595
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。